Prescription To Over-The-Counter Switches Offer Opportunities To Diversify Earnings – Morgan Stanley
This article was originally published in The Pink Sheet Daily
A successful switch could extend a drug’s exclusivity by up to three and a half years, analysts point out.
You may also be interested in...
For all its noise and parties, speeches, and meetings, the 26th annual JP Morgan Healthcare Conference felt more like an indecisive pause than the industry's first step into the new year. Biotech investors see their best exits through M&A, but activity's been unpredictable and less buoyant than expected. But generics and still-impoverished pipelines will force drug companies to make different choices. The quickest solution to pipeline problems is to imitate biotechs by developing or buying biotech products and technologies. These technologies allow Big Pharma to do with biologics what they used to do with small molecules: create fast-followers. Except that there's far more competition this time around.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.